Abstract:Objective: Amygdala-ventrolateral prefrontal cortex (VLPFC) circuitry is disrupted in pediatric anxiety disorders, yet how selective serotonin re -uptake inhibitors (SSRIs) affect this circuitry is unknown. We examined the impact of the SSRI escitalopram on functional connectivity (FC) within this circuit, and whether early FC changes predicted treatment response in adolescents with generalized anxiety disorder (GAD). Method: Resting-state functional magnetic resonance (MR) images were acquired before and after 2 weeks of treatment in 41 adolescents with GAD (12-17 years of age) who received double-blind escitalopram or placebo for 8 weeks. Change in amygdala-based whole-brain FC and anxiety severity were analyzed. Results: Controlling for age, sex, and pretreatment anxiety, escitalopram increased amygdala-VLPFC connectivity compared to placebo (F = 17.79, p = .002 FWE-corrected). This early FC change predicted 76.7% of the variability in improvement trajectory in patients who received escitalopram (p < .001) but not placebo (p = .169); the predictive power of early amygdala-VLPFC FC change significantly differed between placebo and escitalopram (p = .013). Furthermore, this FC change predicted improvement better than baseline FC or clinical/demographic characteristics. Exploratory analyses of amygdala subfields' FC revealed connectivity of left basolateral amygdala (BLA)-VLPFC (F = 19.64, p < .001 FWE-corrected) and superficial amygdala-posterior cingulate cortex (F = 22.92, p = .001 FWE-corrected) were also increased by escitalopram, but only BLA-VLPFC FC predicted improvement in anxiety over 8 weeks of treatment. Conclusion: In adolescents with GAD, escitalopram increased amygdala-prefrontal connectivity within the first 2 weeks of treatment, and the magnitude of this change predicted subsequent clinical improvement. Early normalization of amygdala-VLPFC circuitry might represent a useful tool for identifying future treatment responders as well as a promising biomarker for drug development. Clinical trial registration information: Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety; https:// www.clinicaltrials.gov/; NCT02818751.

General and Anxiety-Linked Influence of Acute Serotonin Reuptake Inhibition on Neural Responses Associated with Attended Visceral Sensation

General and anxiety-linked influences of acute serotonin reuptake inhibition on neural responses associated with attended visceral sensation

Allelic Variation in 5-HTTLPR and the Effects of Citalopram on the Emotional Neural Network.

The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls

Acute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity

Functional brain responses to emotional faces after three to five weeks of intake of escitalopram in healthy individuals: a double-blind, placebo-controlled randomised study

Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study

Central serotonin modulates neural responses to virtual violent actions in emotion regulation networks

Acute SSRI Administration Affects the Processing of Social Cues in Healthy Volunteers

Serotonergic Modulation of Cognition; an Acute Challenge

Effect of short-term escitalopram treatment on neural activation during emotional processing

Acute Neurofunctional Effects of Escitalopram During Emotional Processing in Pediatric Anxiety: a Double-Blind, Placebo-Controlled Trial

Serotonin Enhances the Impact of Health Information on Food Choice

Effect of acute citalopram on self-referential emotional processing and social cognition in healthy volunteers

The Role of Mid-Insula in the Relationship Between Cardiac Interoceptive Attention and Anxiety: Evidence from an Fmri Study

Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial

Fluctuations in [11C]SB207145 PET Binding Associated with Change in Threat-Related Amygdala Reactivity in Humans

Emotion-based brain mechanisms and predictors for SSRI and CBT treatment of anxiety and depression: a randomized trial

Integrin αVβ3 Function Influences Citalopram Immobility Behavior in the Tail Suspension Test

Individual Differences in Threat Sensitivity Predict Serotonergic Modulation of Amygdala Response to Fearful Faces

Dissociable Effects of Acute SSRI (escitalopram) on Executive, Learning and Emotional Functions in Healthy Humans.